Mesoblast Limited (LWB) - Total Liabilities

Latest as of June 2025: €187.24 Million EUR ≈ $218.90 Million USD

Based on the latest financial reports, Mesoblast Limited (LWB) has total liabilities worth €187.24 Million EUR (≈ $218.90 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore LWB cash generation efficiency to assess how effectively this company generates cash.

Mesoblast Limited - Total Liabilities Trend (2014–2025)

This chart illustrates how Mesoblast Limited's total liabilities have evolved over time, based on quarterly financial data. Check Mesoblast Limited asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Mesoblast Limited Competitors by Total Liabilities

The table below lists competitors of Mesoblast Limited ranked by their total liabilities.

Company	Country	Total Liabilities
Sarepta Therapeutics Inc NASDAQ:SRPT	USA	$2.17 Billion
Ningbo Yongxin Optics Co Ltd SHG:603297	China	CN¥412.87 Million
Zhejiang Jingxin Pharmaceutical Co Ltd SHE:002020	China	CN¥2.29 Billion
Fsilon Furnishing and Construction Materials Corp SHG:605318	China	CN¥229.81 Million
Harbin Hatou Investment Co Ltd SHG:600864	China	CN¥33.99 Billion
SIRIUS REAL ESTATE LTD. F:EYI	Germany	€1.66 Billion
Zotye Automobile Co Ltd SHE:000980	China	CN¥3.35 Billion
Streamax Technology Co Ltd SHE:002970	China	CN¥1.19 Billion

Liability Composition Analysis (2014–2025)

This chart breaks down Mesoblast Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Mesoblast Limited market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.99	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.31	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.24	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Mesoblast Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Mesoblast Limited (2014–2025)

The table below shows the annual total liabilities of Mesoblast Limited from 2014 to 2025.

Year	Total Liabilities	Change
2025-06-30	€187.24 Million ≈ $218.90 Million	-0.82%
2024-06-30	€188.80 Million ≈ $220.72 Million	+12.66%
2023-06-30	€167.58 Million ≈ $195.92 Million	+1.50%
2022-06-30	€165.10 Million ≈ $193.02 Million	+1.09%
2021-06-30	€163.32 Million ≈ $190.94 Million	-11.37%
2020-06-30	€184.28 Million ≈ $215.44 Million	+7.72%
2019-06-30	€171.06 Million ≈ $199.99 Million	+16.82%
2018-06-30	€146.44 Million ≈ $171.20 Million	+5.41%
2017-06-30	€138.92 Million ≈ $162.41 Million	-10.87%
2016-06-30	€155.86 Million ≈ $182.21 Million	-50.33%
2015-06-30	€313.78 Million ≈ $366.84 Million	+1.56%
2014-06-30	€308.95 Million ≈ $361.20 Million	--

About Mesoblast Limited

F:LWB Germany Biotechnology

Market Cap

$1.93 Billion

€1.65 Billion EUR

Market Cap Rank

#6527 Global

#957 in Germany

Share Price

€1.28

Change (1 day)

-1.58%

52-Week Range

€0.85 - €1.71

All Time High

€3.48